More Stories

Informist, Friday, Oct. 10, 2025

 

MUMBAI – Shares of pharmaceutical companies are likely to rise next week, boosted by positive triggers including the US Senate passing the Biosecure Act and reports of the US administration likely dropping plans to impose tariffs on generics. Investors will also keep an eye out for the September quarter earnings of Indian drug makers, which are expected to remain resilient despite disruptions in the global trade landscape due to the US tariff threats, according to analysts.  

 

The Biosecure Act, which aims to prohibit federal agencies from giving contracts for biotech equipment or services to companies originating from China, will be beneficial for Indian contract development and manufacturing organisation players as they are likely to get more orders, according to an analyst at a domestic brokerage. "Apart from the Biosecure Act, the reports that the US government doesn't plan to levy generics, added to the positive sentiment, but it was already priced in... with wafer-thin margins in the generics segment in the US, drug makers would not have been able to do business in the country," the analyst said. 

 

On the earnings front, the Indian business of pharmaceutical companies is expected to grow 10-11% and the overall growth is seen at 7-7.5% in the September quarter, according to Mehul Sheth, research analyst at HDFC Securities. "Phasing out of Revlimid may hit sales of some companies, but Lupin will be an outlier whose earnings may remain unaffected," Sheth said.

 

The Nifty Pharma ended the week in green for the second consecutive week. The index rose 2.1% during the week to 22218 points. The biggest gainer was Divi's Laboratories, which rose 10.4% during the week. Friday, Cipla rose 3.2% and was the top performer in the Nifty 50. The Nifty Pharma index is expected to find support at 21600 points and face resistance at 22400 levels, according to Ganesh Angaj, technical analyst at NVS brokerage. 

 

TOP HEADLINES

 

* South Africa co Adcock Ingram shareholders OK stake sale to Natco Pharma arm
* US FDA concludes Emcure Pharma Gujarat unit inspection with no observation
* SC rejects plea for probe into cough syrup-related deaths in some states
* Jubilant Pharmova arm launches new line at Spokane facility in US
* HC junks Roche's injunction plea, allows Natco Pharma to launch risdiplam
* IPO Alert: Rubicon Research's offer subscribed 51% on first day
* Lupin to expand arm's PrescisionSphere long-acting injectable platform
* SC agrees to hear plea for probe into deaths from consuming cough syrup
* IPO Alert: Rubicon Research raises INR 6.19 bln from anchor investors
* NCLT OKs merger of five wholly owned subsidiaries of Sun Pharma with co
* CARE raises Emcure Pharma's long-term bank facilities rating to AA from AA-
* Lupin to build new manufacturing unit in US; to invest $250 mln over 5 yrs
* Nomura says sales growth of Indian pharma mkt slowed to 7.3% YoY in Sept
* Nigerian drug body completes inspection at Concord Biotech's Gujarat unit
* IPO Alert: Rubicon Research sets price band at INR 461-INR 485 per share
* Plea in SC seeks probe into deaths in states due to cough syrup consumption
* Biocon arm, Carnegie Pharma get nod from US FDA for rifaximin tablets
* Zydus Life gets Health Canada approval for generic liothyronine tablets
* Eli Lilly to invest over $1 bln in contract manufacturing ops in India
* Zydus Life gets US FDA final approval for Deflazacort oral suspension
* Lupin's Pithampur Unit-2  gets official action indicated tag from US FDA
* AstraZeneca Pharma gets drug body OK to import, sell trastuzumab deruxtecan
* Lupin launches liraglutide injection for patients with type 2 diabetes in US

 

Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:

Company	Price	Week-on-Week Change in %	Resistance	Support
Abbott India	30130.00	0.60	30706.70	29286.70
Alkem Laboratories	5454.50	0.20	5543.20	5368.20
Aurobindo Pharma	1130.30	3.40	1157.60	1102.80
Biocon	353.45	0.30	362.60	344.00
Cipla	1561.80	2.90	1608.00	1483.80
Divi's Laboratories	6474.50	10.40	6761.50	5966.50
Dr Reddy's Laboratories	1264.40	1.30	1281.90	1235.90
Gland Pharma	1923.40	(-)1.40	1967.90	1893.70
GlaxoSmithKline Pharmaceuticals	2767.40	0.80	2810.10	2712.10
Glenmark Pharmaceuticals	1939.30	(-)2.10	2000.60	1894.40
Granules India	568.55	2.00	582.00	553.50
Ipca Laboratories	1334.50	1.60	1373.20	1311.20
Laurus Labs	876.75	1.40	918.50	822.20
Lupin	1959.30	(-)0.70	2012.00	1905.40
Natco Pharma	845.80	2.80	878.90	817.70
Pfizer	5333.00	2.10	5407.70	5197.70
Sanofi India	4698.90	(-)0.20	4738.80	4671.00
Sun Pharmaceutical Industries	1670.90	2.40	1693.10	1637.90
Torrent Pharmaceuticals	3532.80	0.50	3607.00	3485.00
Zydus Lifesciences	993.45	0.50	1019.80	973.80
Nifty Pharma	22218.25	2.10	22605.90	21655.80
Nifty 50	25285.35	1.60	25431.60	25083.80
S&P Bse Sensex	82500.82	1.60	82990.50	81828.10

 

End

 

Reported by P. Madhu Kumar

Edited by Saji George Titus

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2025. All rights reserved.